Directory · CY
Biotechnology Research in Cyprus
A register of firms and the professionals working at them in the Biotechnology Research sector based in Cyprus. Browse the public index, then filter or export on Kipplo.
Companies
11 on file
Nipd Genetics
NIPD Genetics is officially renamed to Medicover Genetics. Following the acquisition by Medicover, NIPD Genetics rebrands itself as Medicover Genetics, reflecting both the evolution of the company as well as its vision to be a leader in the field of biomedical laboratory testing, placing genetics at the core of medical decisions. With the adoption of the new identity, the Company proudly joins the Medicover family, which consists of an international team of distinguished professionals who share common goals, values, and determination towards fulfilling their mission, which is to enable wider access to advanced genetic services and laboratory solutions. To learn more about us visit: https://medicover-genetics.com/
51 to 200 staff
Novamechanics Ltd
Novamechanics Ltd is a statistical analysis software and an in silico drug design company committed to the computer aided design of small molecules for a very wide range of target classes. The company is focused on the development and implementation of in silico methods to guide decisions in the design and selection of promising drug candidates. Through the combination of industry-recognized expertise, state of the art software and proprietary computing infrastructure, the company's advanced in silico capabilities in molecular design and simulation provide the most effective path to drug innovation. Our mission is to help to bridge the gap between disease targets and optimal quality drug candidates with significantly lower costs and increased potential revenues for our collaborators. NovaMechanics Ltd provides: 1. Bespoke in silico drug design and discovery products and services centred on high throughput computational techniques. Algorithms can rapidly convert ligand information or protein structure information into new chemical designs, maximising the value within the research portfolio of a pharmaceutical partner. Combines expert modelling and first class synthetic chemistry knowledge to ensure that projects are chemistry driven whilst maximising CADD technology. Furthermore the research team has experience in a range of CADD techniques from protein and ligand modelling, structure based design methods, chemoinformatics for data management, ADMET and PBPK models.
11 to 50 staff
Efevre Tech Ltd
EFEVRE TECH LTD (named after a Greek word meaning ‘to invent’), is a Laboratory automation and digitalization provider for Life-science laboratories. EFEVRE TECH LTD was established in Larnaca in June 2018 and is categorized in NACE (Level 3)[7219] Research and Experimental development in natural sciences and engineering. The main focus of EFEVRE TECH LTD is the design, manufacture and retail of prototype/innovative devices that will support the needs of laboratories and industries involved in the field of health science, biology, environmental management and alternative energy around the globe. The purpose of the prototype devices is the automation of multiple procedures in one platform or the redesigning of existing devices in order to save time, energy and money from businesses and research centers. One ambitious project of EFEVRE TECH LTD is the development of AMGL (Automated Molecular and Genetic laboratory), which will automate multiple laboratory procedures in molecular and genetics tests in life science studies. AMGL prototype automated features 1. Liquid handling station This unit will employ automated pipetting system that will transfer reagents from stock solutions to individual working tubes and also offer mixing of solutions through pipetting and vortexing. It also provides heating and cooling using automatically regulated thermoblocks for incubate each mixture of reagents. Centrifugation of each sample 3. Storing of biological reagents and samples: Fridge/freezer for storing a) stock solutions and samples (inputs from user) and b) experimental products (e.g. cell extract) for further usage by scientists 4. Tube transfer system: Responsible for transferring the different tubes to each above-mentioned units. Email: info@efevretech.com, dkyriakou@efevretech.com
1 to 10 staff
V. G. Freyia Labs Ltd
Freyia Labs is a Deeptech, Foodtech, and GreenTech startup pioneering the future of fermentation through technology and sustainability. We combine microbial science with machine learning to build smarter, more resilient food systems. Our platform, F.O.R.S.E.T.I.X.(FX), enables precision-controlled fermentation by equipping small and medium producers with intelligent tools to optimise their fermentation processes. FX uses machine learning to provide real-time monitoring, predictive feedback, and automated control. This helps users reduce batch failures, minimise waste, and consistently produce high-quality fermented products without needing advanced technical expertise. By improving efficiency and consistency, FX helps producers cut costs, scale operations, and meet safety and quality standards while lowering their environmental footprint. We position sustainability as a profit-making strategy for SMEs, enabling them to increase margins through better resource use. We also operate Fire Alchemy by Freyia Labs, a line of functional, fermented foods and condiments that demonstrate the value of modern fermentation in everyday nutrition. Through our collaboration with the UNDP ‘Actions for a Greener Cyprus’, we are applying our F.O.R.S.E.T.I.X. technology beyond food to transform agricultural biomass into natural fertilisers and compost. This demonstrates how our precision-controlled fermentation platform can also drive impact in regenerative agriculture and circular bioeconomy applications. Freyia Labs is rethinking fermentation across sectors to support a Net Zero Food System that is accessible, intelligent, and waste-free. EIT Food, Climate-KIC & Microsoft
1 to 10 staff
Insysbio
InSysBio is a Quantitative Systems Pharmacology (QSP) company established in 2004. Our team has been providing customers with QSP modeling services and tools for more than 10 years. We continuously develop our own QSP platforms and software infrastructure. We assist in making right decisions at critical stages of drug development. Our approach is based on our own cutting-edge methods and software. It enables us to reconstruct the effects of taking medication in terms of clinically measured biomarkers and end-points, predict the efficacy of a drug in humans on the basis of data obtained in animals and in vitro studies, search for optimal combinational therapies, and more. InSysBio has successfully completed more than 100 projects in collaboration with leaders of pharmaceutical industry. Moreover, InSysBio team provides educational assistance to academic entities. To learn more about InSysBio, its solutions, services and tools, visit
11 to 50 staff
Promed Bioscience
We are a highly innovative biotech company developing collagen-based biomaterials to address emergent needs in the research and medical fields. We focus specifically in the development, manufacturing and supply of highly purified research and medical grade collagen. Our collagen products are extracted using proprietary methods under carefully controlled conditions in order to fit specific customer requirements for a wide range of research, clinical and cosmetic/skincare applications.
1 to 10 staff
Epos-Iasis - An Innovative Company - An Eic Declared Global Innovator
EPOS-IASIS is dedicated to addressing the evolving challenges and gaps in chronic disease management. Our vision is to empower individuals at risk of developing systemic malignancies and other multifactorial diseases by providing personalized and multimodality platforms. These innovative solutions, designed for in vivo, minimally invasive, long-term, and sensitive detection, monitoring, and intervention, aim to revolutionize patient care. By significantly enhancing prognosis and survival rates, our platforms will contribute to a paradigm shift in healthcare. EPOS-IASIS envisions leading the way into the multi-billion-dollar field of multifactorial disease molecular theranostics, where precision and efficacy converge for a healthier future. EPOS-IASIS has amassed expertise in translational nanotheranostics, molecular imaging and cell-based technologies, with an emphasis on hybrid (cell + electronics) systems, harnessing molecules and light for faster diagnosis and better prognosis. EPOS-IASIS has established the sole multimodal In Vivo imaging platform on the island (mCT-3DOI-FMT) and the first setting for BRET/FRET technology in the region. It is considered a regional leader in translational nanotheranostics. In the first 13 years of life, EPOS-IASIS has coordinated or participated as a major partner in numerous national and one major FP7-IAPP and H2020 grants, bridging the academic with the entrepreneurial spirit across sectors, amassing more than 5M Euros, including MDCAs, HORIZON-WIDESPREAD-Teaming I (Precision Technologies) and FETOpen. EPOS-IASIS has secured one EPO, one PCT and two USPO patents in theranostics, new CNT-delivery systems for brain tumors and on multifunctional conjugates for metastatic Cancer.
1 to 10 staff
Neema Labs
Crafting biodegradable, eco-friendly materials that reduce carbon emissions, and meet quality standards.
1 to 10 staff
Theramir Ltd
Theramir’s proprietary technologies are based on microRNAs (miRNAs), a class of small non-coding RNAs that can regulate multiple genes and pathways associated with cancer growth and metastasis. The company has developed a panel of miRNAs, both biological and synthetic, which can affect the function and disrupt expression of an expanding list of oncoproteins that are dysregulated in most cancer types. Thus, our technologies can be applied to the development of novel targeted therapeutics that may potentially transform the precision oncology field by creating new knowledge on the pathology of the disease and by enabling the customization and personalization of cancer treatment.
1 to 10 staff
Rsl Revolutionary Labs Ltd
RSL, a healthcare-focused biotech company, offers unique skincare formulations designed in collaboration with scientists, dermatologists and oncology specialists and validated through vigorous R&D and clinical data. Products are all natural, containing no harmful chemicals or preservatives. Key ingredients include collagen, hyaluronic acid and blends of herbal extracts (such as aloe vera, gynura and balsam oil) that provide comfort and relief and help restore the health of patients with compromised skin.
1 to 10 staff
Lifebank Limited
Lifebank Ltd is a private limited liability company registered in the Republic of Cyprus and operating in the field of human tissue and stem cell banking since 2003. The firm’s company-owned laboratory and storage facilities are based in the town of Pafos, Cyprus. Lifebank offers its services in Cyprus, Greece and The Eastern Mediterranean area and operates under a license granted by the Ministry of Health of the Republic of Cyprus. All blood and tissue samples collected are shipped for processing and cryopreservation at the company’s main facilities in Pafos, Cyprus. Lifebank also operates with liaison associates in Syria, Germany, Greece and Bulgaria. The full contact details of Lifebank’s liaisons in these countries can be found on the company’s website at Since its establishment Lifebank closely collaborates with Chaim Sheba Medical Centre, a governmental university hospital in Tel Aviv, Israel. Under this collaboration and as part of an extensive R&D program the two parties have been co-jointly developing new protocols and services in relation to the banking and application of human stem cells. Lifebank’s current business structure constitutes of four business units: 1. Human tissue and stem cell banking division (Lifebank). Liquid nitrogen production and supply division (Medigas). Molecular biology and genetics division (Medgen). Animal tissue and cell cryopreservation division (CryoVet).
1 to 10 staff
